Details
Stereochemistry | RACEMIC |
Molecular Formula | C15H20ClN3O2.ClH.H2O |
Molecular Weight | 364.267 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.Cl.COC1=CC(N)=C(Cl)C=C1C(=O)NC2CN3CCC2CC3
InChI
InChIKey=NPXXKMBXEODDAF-UHFFFAOYSA-N
InChI=1S/C15H20ClN3O2.ClH.H2O/c1-21-14-7-12(17)11(16)6-10(14)15(20)18-13-8-19-4-2-9(13)3-5-19;;/h6-7,9,13H,2-5,8,17H2,1H3,(H,18,20);1H;1H2
Molecular Formula | C15H20ClN3O2 |
Molecular Weight | 309.791 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20950056Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/1514881 | https://www.ncbi.nlm.nih.gov/pubmed/12540230 | https://www.ncbi.nlm.nih.gov/pubmed/24365159 | https://www.ncbi.nlm.nih.gov/pubmed/1312602 | https://www.ncbi.nlm.nih.gov/pubmed/8263156
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20950056
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/1514881 | https://www.ncbi.nlm.nih.gov/pubmed/12540230 | https://www.ncbi.nlm.nih.gov/pubmed/24365159 | https://www.ncbi.nlm.nih.gov/pubmed/1312602 | https://www.ncbi.nlm.nih.gov/pubmed/8263156
Zacopride is a potent antagonist at the 5-HT3 receptor and an agonist at the 5-HT4 receptor with antiemetic, anxiolytic and nootropic effects in animal models. Zacopride also has pro-respiratory effects, both reducing sleep apnea and reversing opioid-induced respiratory depression in animal studies. Zacopride has been tested in clinical trials for the treatment of schizophrenia but was found unsuccessful.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1899 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24365159 |
0.39 nM [Ki] | ||
Target ID: CHEMBL2094132 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1312602 |
1.5 nM [Ki] | ||
Target ID: CHEMBL1875 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12540230 |
5.95 null [pEC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
[3H]5-hydroxytryptamine labels the agonist high affinity state of the cloned rat 5-HT4 receptor. | 1996 May 23 |
|
Opposite effects of antidepressants and corticosterone on the sensitivity of hippocampal CA1 neurons to 5-HT1A and 5-HT4 receptor activation. | 2001 May |
|
Comparison of the effects of 5-HT1A and 5-HT4 receptor activation on field potentials and epileptiform activity in rat hippocampus. | 2002 Dec |
|
Modulation of hippocampal excitability by 5-HT4 receptor agonists persists in a transgenic model of Alzheimer's disease. | 2004 |
|
MD-354 potentiates the antinociceptive effect of clonidine in the mouse tail-flick but not hot-plate assay. | 2004 Jul 14 |
|
Antinociception: mechanistic studies on the action of MD-354 and clonidine. Part 1. The 5-HT3 component. | 2005 Dec 28 |
|
5-HT(3) receptors, alcohol and aggressive behavior in mice. | 2005 May |
|
Imipramine treatment ameliorates corticosterone-induced alterations in the effects of 5-HT1A and 5-HT4 receptor activation in the CA1 area of rat hippocampus. | 2006 Jul |
|
Imipramine and citalopram reverse corticosterone-induced alterations in the effects of the activation of 5-HT(1A) and 5-HT(2) receptors in rat frontal cortex. | 2006 Sep |
|
Effect of itopride hydrochloride on the ileal and colonic motility in guinea pig in vitro. | 2008 Jun 30 |
|
5-Hydroxytryptamine Receptor Subtypes and their Modulators with Therapeutic Potentials. | 2009 Jun |
|
Dose-effect study of Gelsemium sempervirens in high dilutions on anxiety-related responses in mice. | 2010 Jul |
|
Reduced signal transduction by 5-HT4 receptors after long-term venlafaxine treatment in rats. | 2010 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1514881
0.2, 0.4, 0.8 and 1.6 mg/day for 4 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8263156
Adrenal explants, obtained from patients undergoing expanded nephrectomy for kidney cancer, were immediately transported to the laboratory in Dulbecco Modified Eagle’s Medium (DMBM). After dissection and preincubation in DMEM at 20 C, adrenocortical fragments consisting of both glomerulosa and fasciculata zones were mixed with Bio-Gel P2 and transferred into perifusion chambers. Each perifusion column contained approximately 100 mg wet tissue: The perifusion chambers were supplied with DMEM at a constant flow rate (260 mkL/min). The pH (7.4) and temperature (37 C) were kept constant throughout the experiment. The perifusion medium was continuously gassed with a 95% O2-5% CO2 mixture. The tissues were allowed to stabilize for 2 h before zacopride was administered. Zacopride was dissolved in gassed DMEM and infused for 20 min into the perifusion chambers at the same flow rate as DMEM alone by means of a multichannel peristaltic pump. Fractions of the effluent perifusate were collected every 5 min and immediately frozen until assay. Aldosterone and cortisol concentrations were determined by RIA.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:40:57 GMT 2023
by
admin
on
Fri Dec 15 17:40:57 GMT 2023
|
Record UNII |
XL0QQG9B0Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C28197
Created by
admin on Fri Dec 15 17:40:57 GMT 2023 , Edited by admin on Fri Dec 15 17:40:57 GMT 2023
|
||
|
NCI_THESAURUS |
C267
Created by
admin on Fri Dec 15 17:40:57 GMT 2023 , Edited by admin on Fri Dec 15 17:40:57 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C055971
Created by
admin on Fri Dec 15 17:40:57 GMT 2023 , Edited by admin on Fri Dec 15 17:40:57 GMT 2023
|
PRIMARY | |||
|
DTXSID4045686
Created by
admin on Fri Dec 15 17:40:57 GMT 2023 , Edited by admin on Fri Dec 15 17:40:57 GMT 2023
|
PRIMARY | |||
|
19849157
Created by
admin on Fri Dec 15 17:40:57 GMT 2023 , Edited by admin on Fri Dec 15 17:40:57 GMT 2023
|
PRIMARY | |||
|
CHEMBL18041
Created by
admin on Fri Dec 15 17:40:57 GMT 2023 , Edited by admin on Fri Dec 15 17:40:57 GMT 2023
|
PRIMARY | |||
|
99617-34-2
Created by
admin on Fri Dec 15 17:40:57 GMT 2023 , Edited by admin on Fri Dec 15 17:40:57 GMT 2023
|
PRIMARY | |||
|
C152943
Created by
admin on Fri Dec 15 17:40:57 GMT 2023 , Edited by admin on Fri Dec 15 17:40:57 GMT 2023
|
PRIMARY | |||
|
XL0QQG9B0Y
Created by
admin on Fri Dec 15 17:40:57 GMT 2023 , Edited by admin on Fri Dec 15 17:40:57 GMT 2023
|
PRIMARY | |||
|
X-68
Created by
admin on Fri Dec 15 17:40:57 GMT 2023 , Edited by admin on Fri Dec 15 17:40:57 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |